Literature DB >> 2421587

Vasoactive intestinal peptide receptor antagonist [4Cl-D-Phe6, Leu17] VIP.

S J Pandol, K Dharmsathaphorn, M S Schoeffield, W Vale, J Rivier.   

Abstract

From structure-activity relationship studies of rat growth hormone-releasing factor (rGFR) on the vasoactive intestinal peptide (VIP) receptor in an in vitro preparation of exocrine pancreas, we predicted that [4Cl-D-Phe6, Leu17]VIP would be a competitive antagonist for the action of VIP. Micromolar concentrations of synthetic [4Cl-D-Phe6, Leu17]VIP competitively antagonized VIP-stimulated amylase release in the pancreatic preparation and VIP-stimulated short-circuit current changes in a colonic tumor cell line. In addition, [4Cl-D-Phe6, Leu17]VIP inhibited amylase release stimulated by rGRF, high concentrations of secretin (agents that act through the VIP receptor), and peptide contaminants in a preparation of natural glucagon. Finally, [4Cl-D-Phe6, Leu17]VIP did not inhibit the action of agonists for the secretin, GRF, or glucagon receptors.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2421587     DOI： 10.1152/ajpgi.1986.250.4.G553

Source DB:  PubMed          Journal:  Am J Physiol        ISSN： 0002-9513


  34 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  Antisecretory actions of a novel vasoactive intestinal polypeptide (VIP) antagonist in human and rat small intestine.

Authors:  Matthew R Banks; Michael J G Farthing; Patrick Robberecht; David E Burleigh
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  A glucagon-secretin-like peptide stimulates the intrinsic nervous plexus of guinea pig gallbladder.

Authors:  A V Greco; R Mancinelli; G Mingrone; C Racanicchi
Journal:  Experientia       Date:  1990-05-15

4.  Vasoactive intestinal peptide stimulation of human renal adenylate cyclase in vitro.

Authors:  B G Charlton; D E Neal; N L Simmons
Journal:  J Physiol       Date:  1990-04       Impact factor: 5.182

Review 5.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

6.  The influence of the trigeminal ganglion on carotid blood flow in anaesthetized guinea-pigs.

Authors:  D T Beattie; H E Connor
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission.

Authors:  Y M Qian; R L Jones
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

8.  Role of vasoactive intestinal peptide (VIP) in pathogenesis of ethanol-induced gastric mucosal damage in rats.

Authors:  F Karmeli; R Eliakim; E Okon; D Rachmilewitz
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

9.  VIP antagonists enhance excitatory cholinergic neurotransmission in the human airway.

Authors:  H Aizawa; H Inoue; M Shigyo; S Takata; H Koto; K Matsumoto; N Hara
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  Circadian integration of glutamatergic signals by little SAAS in novel suprachiasmatic circuits.

Authors:  Norman Atkins; Jennifer W Mitchell; Elena V Romanova; Daniel J Morgan; Tara P Cominski; Jennifer L Ecker; John E Pintar; Jonathan V Sweedler; Martha U Gillette
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.